ABSTRACT
In 80% of children suffering from immune thrombocytopenic purpura, the disease is a self-limited process. Established therapeutic measures are commonly used to effect symptomatic relief. The foremost of these is the administration of immunoglobulins and corticosteroids. A total of 113 children and adolescents with immune thrombocytopenic purpura were examined retrospectively in this study. Of these, 48%, did not require any therapy, 37% were treated with high-dose immunoglobulin, and 15% with prednisolone as first-line treatment of extensive purpura of the skin and the mucous membrane. The time until the thrombocyte count reached 100 G/l was shorter in the treated group than in the one that was not treated (4.5 and 6.0 versus 21 days). 71% of all patients achieved remission in six month. In 29% the disease took a chronic course. Of 33 children with chronic therapy-dependent disease, 7 were splenectomised successfully. Seven further patients continue to live with thrombocyte counts below 20 G/l, of which 4 suffer from recurrent bleeding episodes. In patients with acute and chronic immune thrombocytopenic purpura, the aim of treatment is to prevent potentially fatal bleeding. Patients with thrombocyte counts below 20 G/l are high-risk patients. Nevertheless, even in this group, the therapy should be decided clinically according to bleeding tendency. Ideally, the therapy should result in a quick increase of thrombocyte counts whilst causing minimum side effects. Of the various established treatment modalities, high-dose immunoglobulin and high-dose prednisolone best fulfil these requirements.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Immunization, Passive , Purpura, Thrombocytopenic, Idiopathic/therapy , Adolescent , Child , Child, Preschool , Chronic Disease , Combined Modality Therapy , Dose-Response Relationship, Drug , Female , Humans , Infant , Male , Platelet Count/drug effects , Prednisolone/administration & dosage , Purpura, Thrombocytopenic, Idiopathic/immunology , Retrospective Studies , Treatment OutcomeABSTRACT
A total of 203 paediatric cancer treatment survivors were tested for serum antibodies against hepatitis-C virus (anti-HCV). Anti-HCV was detected in 41 patients (20.2%) with first generation anti-HCV ELISA. Positive results were confirmed in all samples retested with a second generation ELISA (n = 35) and in all but two cases re-analysed by immunoblotting (n = 23). Anti-HCV positive children had received significantly more blood product transfusions compared to seronegative patients. In 75 children (32%) chronic liver disease was found. It was defined as an elevation of serum alanine aminotransferase values to a least 2.5 times the upper limit of normal persisting for 6 months or longer. Hepatitis A was never detected, and in 58 children the chronic hepatopathy was unexplained by hepatitis B (non-A non-B chronic liver disease). Of these patients 29 (50%) were seropositive for anti-HCV. Surprisingly, non-A/non-B chronic liver disease was associated with anti-HCV in 14 of 19 solid tumour patients (78.9%), but in no more than 14 of 39 leukaemia and lymphoma patients (35.9%). This phenomenon was not explained by different rates of cytomegalovirus disease and drug toxicity related hepatopathies between the two groups. It may be related to differences of leukaemia/lymphoma compared to solid tumour therapy schedules (differential immunosuppression and liver toxicity).
Subject(s)
Hepacivirus/immunology , Hepatitis Antibodies/blood , Hepatitis C/immunology , Neoplasms/immunology , Child , Chronic Disease , Enzyme-Linked Immunosorbent Assay , Female , Hepatitis C/complications , Hepatitis C Antibodies , Humans , Liver Diseases/complications , Liver Diseases/immunology , Male , Neoplasms/complications , Neoplasms/therapyABSTRACT
The prevalence of hepatitis-C virus (HCV) infection was investigated in a group of children with chronic post-transfusion hepatitis using a first- and second-generation HCV-antibody ELISA, 2 confirmatory tests (a second-generation recombinant immunoblot assay and a line immunoassay) as well as an HCV-polymerase chain reaction (PCR). In 33% of the children, clear discrepancies were observed between the 4 different HCV-antibody detection assays, indicating that the serological diagnosis of HCV infection is still problematic. HCV RNA was detectable by PCR in only 69% of the antibody positive patients, which may be due to a fluctuation of viraemia during the course of infection. Such a fluctuation was demonstrated in 6 patients from whom serum samples drawn at different times were investigated. In contrast, in 8 of the 15 seronegative patients, HCV infection was identified only by PCR, although the hepatitis had already persisted for more than 2 years. Antibody assays and PCR together detected HCV infection in about 90% of the patients with chronic hepatitis. When markers of hepatitis B infection were also investigated, only 6% of the cases remained undiagnosed.
